Not applicableLooking for participantsNCT05489783What this trial is testingGlioma Developmental and HyperActive Ras Tumor (DHART) BoardWho this might be right forGlioma Memorial Sloan Kettering Cancer Center 50
Testing effectiveness (Phase 2)Looking for participantsNCT06666348What this trial is testingPhase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPKWho this might be right forPediatric Low-grade Glioma St. Justine's Hospital 50
Not applicableStudy completedNCT00684398What this trial is testingAdaptation and Quality of Life Among Adults With Neurofibromatosis Type IWho this might be right forNeurofibromatosis Type 1Von Recklinghausen DiseaseNF1 National Human Genome Research Institute (NHGRI) 645
Not applicableLooking for participantsNCT05954416What this trial is testingFARD (RaDiCo Cohort) (RaDiCo-FARD)Who this might be right forInherited Epidermolysis BullosaIchthyosisEctodermal Dysplasia+6 more Institut National de la Santé Et de la Recherche Médicale, France 900
Early research (Phase 1)Study completedNCT00901849What this trial is testingTarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)Who this might be right forLow-grade Gliomas Roger Packer 21
Testing effectiveness (Phase 2)WithdrawnNCT03109301What this trial is testingMitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)Who this might be right forNeoplasms, Nerve TissueNeurofibromatosis 1Heredodegenerative Disorders, Nervous System+1 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT03232892What this trial is testingTrametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer University of California, San Francisco 1
Not applicableStudy completedNCT03888248What this trial is testingWhole-body Vibration in Children With Neurofibromatosis Type 1Who this might be right forNeurofibromatosis Type 1Muscle Weakness Manchester University NHS Foundation Trust 30
Early research (Phase 1)Active Not RecruitingNCT05101148What this trial is testingPhase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasWho this might be right forNeurofibromatosis Type 1 AstraZeneca 24
Early research (Phase 1)Study completedNCT06120036What this trial is testingDosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous NeurofibromasWho this might be right forNeurofibromatosis 1 Massachusetts General Hospital 20
Not applicableUnknownNCT03757247What this trial is testingPrevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 MutationWho this might be right forNeurofibromatosis Type 1 Medical University Innsbruck 670
Not applicableStudy completedNCT03672838What this trial is testingA Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)Who this might be right forNeurofibromatosis 1 and 2 (NF1 and NF2) NYU Langone Health 33
Testing effectiveness (Phase 2)Study completedNCT01207687What this trial is testingBevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)Who this might be right forVestibular SchwannomaNeurofibromatosis Type 2 National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Study completedNCT00076102What this trial is testingPirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasWho this might be right forNeurofibromatosis 1Neurofibroma, Plexiform National Cancer Institute (NCI) 36
Not applicableStudy completedNCT01707836What this trial is testingNeurofibromatosis Type 1 Brain Tumor Genetic RiskWho this might be right forNeurofibromatosis Type 1Pediatric Brain Tumor Washington University School of Medicine 176
Not applicableAvailableNCT05028166What this trial is testingIndividual Patient Compassionate Use of MirdametinibWho this might be right forNeurofibromatosis Type 1-Associated Plexiform NeurofibromasHistiocytic NeoplasmOther MAP-K Pathway Driven Diseases SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Large-scale testing (Phase 3)Ended earlyNCT03710564What this trial is testingStudy of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF InjectionsWho this might be right forAge-Related Macular Degeneration Novartis Pharmaceuticals 535
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07521657What this trial is testingEfficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaWho this might be right forNeurofibromatosis 1 (NF1) University of Alabama at Birmingham 55
Very early researchStudy completedNCT00863122What this trial is testingConcentration and Activity of Lapatinib in Vestibular SchwannomasWho this might be right forVestibular SchwannomaNF2Neurofibromatosis 2+2 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Early research (Phase 1)Looking for participantsNCT07102394What this trial is testingFeasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Who this might be right forNF1NeurofibromatosisCutaneous Neurofibroma+3 more Johns Hopkins University 10